Heidi Chokeir
@biotechheidi
Biotech PR Goddess at Evoke Canale. Wine lover. Quilt maker. Passionate about cooking amazing food for people I love.
ID: 268372589
http://www.facebook.com/heidi.chokeir 18-03-2011 16:51:31
2,2K Tweet
813 Followers
852 Following
Great piece by Bruce Booth that reminds us of what lurks underneath the zoom persona -- real people with real pain. Personal Reflection: Empathy In The Workplace lifescivc.com/2021/03/person…
Couldn't ask for a more intelligent and passionate scientist to lead the La Jolla Institute for Immunology than my dear friend Erica Ollmann Saphire Erica OllmannSaphire ! lji.org/news-events/ne…
Interested in working with a great group of journalists during one of the most important times for health news? We've got two health editing jobs at The Wall Street Journal: Health Business Bureau Chief and Health & Science News Editor. You can find them here: wsj.jobs
#transcript Dr. Steve Worland #eFFECTORTherapeutics Genomics 3.0 pioneer in selective translation regulator inhibitors #STRIs Two #cancer revolutions targeted therapies & #immunotherapies. STRIs 3rd way to compliment one or both of those.#NSCLC #SPAC empoweredpatientradio.com/using-selectiv…
Congratulations to the Qpex Biopharma team on publishing on the chemical development for Phase 3 readiness of the ultra-broad spectrum inhibitor QPX7728 that can be delivered IV and orally. BARDA Antimicrobials Working Group Global Antibiotic R&D Partnership (GARDP) AMR Action Fund
Great Op/Ed in The San Diego Union-Tribune. Such an important conversation that needs to be had, given the global threat of antimicrobial resistance. We need to do better! How do we make the shift? BARDA Antimicrobials Working Group Global Antibiotic R&D Partnership (GARDP) AMR Action Fund Scott Gottlieb, MD 🇺🇸
Our CEO Kevin Appelbaum sat down with Jonathan D. Grinstein, PhD of @GENBio to discuss the bold vision behind our company – a new way to treat age-old diseases, starting with #type2diabetes. Read the full piece here: genengnews.com/cardiovascular…
Our CEO Dr. Paul Peter Tak was included in Scrip, Citeline Commercial annual outlook feature sharing his anticipations on the industry at large and within the immuno-oncology space. Read the full piece here: bit.ly/3sZhBNc